Back to top
more

ADMA Biologics (ADMA)

(Delayed Data from NSDQ)

$6.46 USD

6.46
1,704,207

-0.08 (-1.22%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $6.46 0.00 (0.00%) 7:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake

by Zacks Equity Research

Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.

Kinjel Shah headshot

Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?

by Kinjel Shah

Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.

Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why

by Zacks Equity Research

Adma Biologics (ADMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study

by Zacks Equity Research

Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.

Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study

by Zacks Equity Research

Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.

Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies

by Zacks Equity Research

Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.

Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?

by Zacks Equity Research

Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024.

Here's Why You Should Add Immunovant (IMVT) to Your Portfolio

by Zacks Equity Research

Immunovant's (IMVT) late-stage studies evaluating its lead candidate, batoclimab, for various autoimmune indications are progressing well. Several data readouts are expected in 2024 and 2025.

Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note

by Zacks Equity Research

In the most recent trading session, Adma Biologics (ADMA) closed at $6.27, indicating a +1.13% shift from the previous trading day.

Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug

by Zacks Equity Research

Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.

Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study

by Zacks Equity Research

Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.

Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion

by Zacks Equity Research

Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.

Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal

by Zacks Equity Research

Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.

DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch

by Zacks Equity Research

DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.

Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up

by Zacks Equity Research

Vanda's (VNDA) board of directors unanimously rejects takeover proposals from Future Pak to acquire all outstanding shares of Vanda. Shares rise on the news.

Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note

by Zacks Equity Research

In the most recent trading session, Adma Biologics (ADMA) closed at $6.04, indicating a -1.95% shift from the previous trading day.

2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why

by Zacks Equity Research

The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.

Are Medical Stocks Lagging Annexon (ANNX) This Year?

by Zacks Equity Research

Here is how Annexon, Inc. (ANNX) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals

by Zacks Equity Research

Intra-Cellular (ITCI) jumps 23% after achieving key goals in the late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.

GSK Announces FDA Acceptance of New Meningococcal Jab BLA

by Zacks Equity Research

The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.

bluebird (BLUE) Underperforms Industry YTD Amid Challenges

by Zacks Equity Research

bluebird (BLUE) plunges 25% year to date as it struggles to fuel the growth of its complex and expensive gene therapies.

Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why

by Zacks Equity Research

Aptevo (APVO) plunges after it issues secondary shares, which are not only issued at a significant discount but also substantially dilute the existing shareholder base.

Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study

by Zacks Equity Research

Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.

Corcept (CORT) Completes Enrollment in Phase II ALS Study

by Zacks Equity Research

The phase II DAZALS study is evaluating Corcept's (CORT) dazucorilant for treating patients with amyotrophic lateral sclerosis. Enrollment in the study is already complete.

Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study

by Zacks Equity Research

Ultragenyx (RARE) reports positive interim data from the phase I/II study of GTX-102 for Angelman syndrome. However, the stock declines due to safety concerns.